[Form 4] PLUS THERAPEUTICS, Inc. Insider Trading Activity
Richard J. Hawkins, a director of Plus Therapeutics, Inc. (PSTV), reported receipt of a stock option grant on 08/13/2025. The award is a stock option with an exercise price of $0.5744 covering 397,794 underlying shares. Following the reported transaction, the reporting person beneficially owns 397,794 shares on a direct basis. The option vests monthly over 12 months from the grant date and will vest in full at the issuer's 2026 annual stockholder meeting, subject to continued service. The option has an expiration date shown as 08/12/2035. The Form 4 was signed by an attorney-in-fact, Andrew Sims, on 08/15/2025.
Richard J. Hawkins, membro del consiglio di amministrazione di Plus Therapeutics, Inc. (PSTV), ha dichiarato di aver ricevuto un鈥檕pzione su azioni in data 13/08/2025. L鈥檃ssegno consiste in un鈥檕pzione con prezzo di esercizio pari a $0,5744 su 397.794 azioni sottostanti. A seguito dell鈥檕perazione comunicata, il soggetto segnalante detiene beneficiariamente 397.794 azioni a titolo diretto. L鈥檕pzione matura mensilmente nel corso di 12 mesi a partire dalla data di concessione e verr脿 acquisita integralmente in occasione dell鈥檃ssemblea annuale degli azionisti dell鈥檈mittente del 2026, subordinatamente alla continuazione del rapporto di servizio. L鈥檕pzione scade il 12/08/2035. Il Modulo 4 猫 stato firmato per procura dall鈥檃vvocato Andrew Sims in data 15/08/2025.
Richard J. Hawkins, director de Plus Therapeutics, Inc. (PSTV), inform贸 la recepci贸n de una opci贸n sobre acciones el 13/08/2025. La concesi贸n es una opci贸n con un precio de ejercicio de $0.5744 que cubre 397,794 acciones subyacentes. Tras la operaci贸n informada, la persona informante posee beneficiariamente 397,794 acciones a t铆tulo directo. La opci贸n devenga mensualmente durante 12 meses desde la fecha de concesi贸n y se har谩 efectiva en su totalidad en la junta anual de accionistas del emisor de 2026, sujeta a la continuidad del servicio. La opci贸n tiene fecha de vencimiento el 12/08/2035. El Formulario 4 fue firmado por apoderado, Andrew Sims, el 15/08/2025.
Richard J. Hawkins电� Plus Therapeutics, Inc. (PSTV)鞚� 鞚挫偓搿滌劀 2025-08-13鞐� 鞀ろ啞鞓奠厴鞚� 靾橂牴頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 靾橃棳霅� 氤挫儊鞚� 頄夓偓臧� $0.5744鞚� 鞀ろ啞鞓奠厴鞙茧, 397,794欤茧ゼ 旮办磮搿� 頃╇媹雼�. 氤搓碃霅� 瓯半灅 頉� 頃措嫻 氤搓碃鞚胳潃 歆侅爲鞝侅溂搿� 397,794欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚� 鞓奠厴鞚� 靾橃棳鞚茧攵�韯� 12臧滌洈 霃欖晥 毵れ洈 氩犾姢韺呺悩氅�, 瓿勳啀 攴茧 臁瓣贝 頃橃棎 氚滍枆靷潣 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 鞝勳暋 氩犾姢韺呺惄雼堧嫟. 鞓奠厴鞚� 毵岆鞚检潃 2035-08-12搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. Form 4电� Andrew Sims 雽�毽澑(氤�順胳偓)鞐� 鞚橅暣 2025-08-15鞐� 靹滊獏霅橃棃鞀惦媹雼�.
Richard J. Hawkins, administrateur de Plus Therapeutics, Inc. (PSTV), a d茅clar茅 avoir re莽u une option d鈥檃chat d鈥檃ctions le 13/08/2025. L鈥檃ttribution porte sur une option d鈥檃chat avec un prix d鈥檈xercice de 0,5744 $ couvrant 397 794 actions sous-jacentes. 脌 la suite de la transaction d茅clar茅e, la personne d茅clarante d茅tient 脿 titre b茅n茅ficiaire 397 794 actions en direct. L鈥檕ption acquiert des droits mensuellement sur 12 mois 脿 compter de la date d鈥檃ttribution et sera enti猫rement acquise lors de l鈥檃ssembl茅e g茅n茅rale annuelle de l鈥櫭﹎etteur en 2026, sous r茅serve de la poursuite du service. L鈥檕ption expire le 12/08/2035. Le formulaire 4 a 茅t茅 sign茅 par un mandataire, Andrew Sims, le 15/08/2025.
Richard J. Hawkins, ein Direktor von Plus Therapeutics, Inc. (PSTV), meldete den Erhalt einer Aktienoption am 13.08.2025. Die Zuwendung ist eine Option mit einem Aus眉bungspreis von $0,5744, die 397.794 zugrunde liegende Aktien abdeckt. Nach der gemeldeten Transaktion besitzt die meldende Person wirtschaftlich 397.794 Aktien unmittelbar. Die Option wird ab dem Gew盲hrungsdatum 眉ber 12 Monate monatlich freigegeben und f盲llt, vorbehaltlich fortgesetzter Dienstzeit, vollst盲ndig bei der ordentlichen Hauptversammlung des Emittenten 2026 an. Die Option l盲uft am 12.08.2035 ab. Das Formblatt 4 wurde am 15.08.2025 von einem Bevollm盲chtigten, Andrew Sims, unterzeichnet.
- Alignment of interests: Time-based vesting ties the director's compensation to continued service and shareholder outcomes.
- Transparent reporting: The Form 4 discloses option terms, quantity, strike price, vesting schedule, and ownership form.
- Potential dilution: Grant of 397,794 options could dilute existing shareholders if exercised.
- No performance conditions disclosed: Vesting is service-based only, not tied to operational or financial milestones.
Insights
TL;DR: A director received a sizable option grant (397,794 shares) at a low strike, increasing potential dilution but aligning incentives.
The grant of 397,794 options at a $0.5744 exercise price represents meaningful equity compensation for a director relative to typical board awards for smaller companies. The monthly vesting over 12 months, with full vesting tied to the 2026 annual meeting, ties rewards to continued service and near-term shareholder outcomes. This is a compensation-related disclosure rather than an open-market purchase or sale. Investors should note the direct beneficial ownership reported equals the number of options granted under the Form 4, and the option term extends to the mid-2030s, allowing long-term optionality for the holder.
TL;DR: The filing documents a routine director option award with time-based vesting and an attorney-in-fact signature.
The structure鈥攎onthly vesting over 12 months and accelerated full vesting at the next annual meeting鈥攁ppears designed to retain the director through an upcoming corporate milestone. The filing is properly reported on Form 4 with direct beneficial ownership disclosed. The use of an attorney-in-fact to sign the form reflects standard administrative handling of filing logistics. There is no disclosure of performance-based vesting conditions in this filing; vesting is service-based.
Richard J. Hawkins, membro del consiglio di amministrazione di Plus Therapeutics, Inc. (PSTV), ha dichiarato di aver ricevuto un鈥檕pzione su azioni in data 13/08/2025. L鈥檃ssegno consiste in un鈥檕pzione con prezzo di esercizio pari a $0,5744 su 397.794 azioni sottostanti. A seguito dell鈥檕perazione comunicata, il soggetto segnalante detiene beneficiariamente 397.794 azioni a titolo diretto. L鈥檕pzione matura mensilmente nel corso di 12 mesi a partire dalla data di concessione e verr脿 acquisita integralmente in occasione dell鈥檃ssemblea annuale degli azionisti dell鈥檈mittente del 2026, subordinatamente alla continuazione del rapporto di servizio. L鈥檕pzione scade il 12/08/2035. Il Modulo 4 猫 stato firmato per procura dall鈥檃vvocato Andrew Sims in data 15/08/2025.
Richard J. Hawkins, director de Plus Therapeutics, Inc. (PSTV), inform贸 la recepci贸n de una opci贸n sobre acciones el 13/08/2025. La concesi贸n es una opci贸n con un precio de ejercicio de $0.5744 que cubre 397,794 acciones subyacentes. Tras la operaci贸n informada, la persona informante posee beneficiariamente 397,794 acciones a t铆tulo directo. La opci贸n devenga mensualmente durante 12 meses desde la fecha de concesi贸n y se har谩 efectiva en su totalidad en la junta anual de accionistas del emisor de 2026, sujeta a la continuidad del servicio. La opci贸n tiene fecha de vencimiento el 12/08/2035. El Formulario 4 fue firmado por apoderado, Andrew Sims, el 15/08/2025.
Richard J. Hawkins电� Plus Therapeutics, Inc. (PSTV)鞚� 鞚挫偓搿滌劀 2025-08-13鞐� 鞀ろ啞鞓奠厴鞚� 靾橂牴頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 靾橃棳霅� 氤挫儊鞚� 頄夓偓臧� $0.5744鞚� 鞀ろ啞鞓奠厴鞙茧, 397,794欤茧ゼ 旮办磮搿� 頃╇媹雼�. 氤搓碃霅� 瓯半灅 頉� 頃措嫻 氤搓碃鞚胳潃 歆侅爲鞝侅溂搿� 397,794欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞚� 鞓奠厴鞚� 靾橃棳鞚茧攵�韯� 12臧滌洈 霃欖晥 毵れ洈 氩犾姢韺呺悩氅�, 瓿勳啀 攴茧 臁瓣贝 頃橃棎 氚滍枆靷潣 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 鞝勳暋 氩犾姢韺呺惄雼堧嫟. 鞓奠厴鞚� 毵岆鞚检潃 2035-08-12搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. Form 4电� Andrew Sims 雽�毽澑(氤�順胳偓)鞐� 鞚橅暣 2025-08-15鞐� 靹滊獏霅橃棃鞀惦媹雼�.
Richard J. Hawkins, administrateur de Plus Therapeutics, Inc. (PSTV), a d茅clar茅 avoir re莽u une option d鈥檃chat d鈥檃ctions le 13/08/2025. L鈥檃ttribution porte sur une option d鈥檃chat avec un prix d鈥檈xercice de 0,5744 $ couvrant 397 794 actions sous-jacentes. 脌 la suite de la transaction d茅clar茅e, la personne d茅clarante d茅tient 脿 titre b茅n茅ficiaire 397 794 actions en direct. L鈥檕ption acquiert des droits mensuellement sur 12 mois 脿 compter de la date d鈥檃ttribution et sera enti猫rement acquise lors de l鈥檃ssembl茅e g茅n茅rale annuelle de l鈥櫭﹎etteur en 2026, sous r茅serve de la poursuite du service. L鈥檕ption expire le 12/08/2035. Le formulaire 4 a 茅t茅 sign茅 par un mandataire, Andrew Sims, le 15/08/2025.
Richard J. Hawkins, ein Direktor von Plus Therapeutics, Inc. (PSTV), meldete den Erhalt einer Aktienoption am 13.08.2025. Die Zuwendung ist eine Option mit einem Aus眉bungspreis von $0,5744, die 397.794 zugrunde liegende Aktien abdeckt. Nach der gemeldeten Transaktion besitzt die meldende Person wirtschaftlich 397.794 Aktien unmittelbar. Die Option wird ab dem Gew盲hrungsdatum 眉ber 12 Monate monatlich freigegeben und f盲llt, vorbehaltlich fortgesetzter Dienstzeit, vollst盲ndig bei der ordentlichen Hauptversammlung des Emittenten 2026 an. Die Option l盲uft am 12.08.2035 ab. Das Formblatt 4 wurde am 15.08.2025 von einem Bevollm盲chtigten, Andrew Sims, unterzeichnet.
FAQ
What did Richard J. Hawkins report on the Form 4 for PSTV?
When do the options vest and when do they expire?
How is ownership reported on this Form 4 for PSTV?
Who signed the Form 4 and when?
Does the filing disclose any performance-based vesting conditions?
